https://www.estrellabio.com/news/estrella-immunopharma%2C-inc.-(nasdaq%3A-esla)-receives-initiating-coverage-with-a-valuation-of-%2412.00%2Fshare-from-zacks-small-cap-research 2026-03-23 https://www.estrellabio.com/news/estrella-immunopharma-presents-promising-updated-data-on-eb103-in-oral-presentation-at-the-2026-tandem-meetings-of-astct%C2%AE-%26-cibmtr%C2%AE 2026-02-09 https://www.estrellabio.com/news/estrella-immunopharma-announces-late-breaking-oral-presentation-of-phase-1-starlight-1-data-for-eb103-at-the-2026-tandem-meetings-of-astct%C2%AE-%26-cibmtr%C2%AE 2026-02-02 https://www.estrellabio.com/news/estrella-immunopharma-announces-closing-of-%248.0-million-registered-direct-offering-and-concurrent-private-placement 2026-01-06 https://www.estrellabio.com/news/estrella-announces-%248.0-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules 2026-01-06 https://www.estrellabio.com/news/estrella-advances-starlight-1-trial-into-phase-ii-following-positive-dsmb-recommendation 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-of-eb103-with-complete-responses-in-all-evaluable-patients 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-regains-compliance-with-nasdaq-listing-requirements 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-announces-activation-of-additional-site-for-phase-i%2Fii-starlight-1-trial-in-b-cell-non-hodgkin%E2%80%99s-lymphoma 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-announces-approximately-%243.35-million-private-placement-equity-financing 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-initiates-second-cohort-and-doses-first-patient-in-starlight-1-trial-of-eb103-in-advanced-b-cell-non-hodgkin%E2%80%99s-lymphomas 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma%2C-inc.-(nasdaq%3A-esla)-receives-buy-rating-with-a-price-target-of-%2414.00-from-cb-capital-partners- 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-completes-first-dose-cohort-in-starlight-1-trial-and-receives-approval-to-initiate-higher-dose-cohort 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma%2C-inc.-(nasdaq%3A-esla%3B-eslaw)-receives-buy-rating-with-a-12-month-price-target-of-%2416.00-from-d.-boral-capital 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-achieves-complete-response-in-first-patient-treated-with-cd19--redirected-artemis%C2%AE-t-cells 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-announces-appointment-of-hong-zhang-as-chairperson-and-board-member 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-doses-first-patient-in-phase-i%2Fii-trial-of-eb103-in-advanced-b-cell-non-hodgkin%E2%80%99s-lymphomas 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-announces-%241-million-share-repurchase-authorization- 2025-12-03 https://www.estrellabio.com/news/estrella-immunopharma-announces-publication-in-blood-demonstrating-artemis-t-cell%E2%80%99s-potential-in-addressing-acute-myeloid-leukemia-(aml)- 2025-12-03 https://www.estrellabio.com/news/tradeup-acquisition-corp.-and-estrella-biopharma%2C-inc.-announce-completion-of-business-combination 2025-12-03 https://www.estrellabio.com/news/estrella-biopharma-announces-fda-clearance-of-ind-application-for-phase-i%2Fii-clinical-trial-(starlight-1)-of-eb103%2C-a-cd19-targeted-artemis%C2%AE-t-cell-therapy%2C-to-patients-with-b-cell-lymphomas 2025-12-03 https://www.estrellabio.com/news/imugene%E2%80%99s-oncarlytics-combination-with-estrella%E2%80%99s-cd19-redirected-artemis%C2%AE-t-cells-presented-at-sitc-annual-meeting 2025-12-03 https://www.estrellabio.com/news/estrella-biopharma%2C-inc.%2C-a-biopharmaceutical-company-to-become-a-publicly-traded-company-via-merger-with-tradeup-acquisition-corp.- 2025-12-03